Please provide your email address to receive an email when new articles are posted on . The addition of blinatumomab to chemotherapy improved DFS for children with B-cell ALL. Researchers stopped ...

Discover comprehensive details about Blinatumomab, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

Please provide your email address to receive an email when new articles are posted on . Results of two studies published in JAMA showed the addition of blinatumomab to consolidation chemotherapy ...

A significant survival improvement finding for adults with newly diagnosed BCR::ABL1-negative B-cell precursor acute lymphoblastic leukemia appears in the New England Journal of Medicine. The practice ...

COPENHAGEN, Denmark ― Monotherapy with the novel antibody blinatumomab (Blincyto, Amgen Inc) beat standard chemotherapy, significantly improving overall survival in adult patients with ...

Blinatumomab addition to chemotherapy significantly improves survival and reduces relapse in pediatric B-cell acute lymphoblastic leukemia, especially in high-risk groups. The trial demonstrated that ...

A study led by The University of Texas MD Anderson Cancer Center showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab resulted in ...

A study presented at the American Society of Hematology annual meeting identified TCL1A as a potential predictive biomarker for blinatumomab (Blincyto) response in relapsed pediatric B-cell acute ...

The US Food and Drug Administration (FDA) has granted full approval to blinatumomab (Blincyto, Amgen) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in ...

Consolidation therapy with blinatumomab significantly improves overall survival (OS) in adult patients newly diagnosed with B-cell acute lymphoblastic leukemia (B-ALL) who had no measurable residual ...

A study led by The University of Texas MD Anderson Cancer Center showed that first-line treatment with a regimen of chemotherapy combined with the monoclonal antibody blinatumomab resulted in ...